The biotech industry appeared to be free of Genentech, Inc.’s Cabilly patents, which cover a method of manufacturing antibodies, when they expired in December 2018. But Genentech claims that Biogen, Inc. and Millennium Pharmaceuticals still must pay royalties on sales of Tysabri (natalizumab) and Entyvio (vedolizumab), respectively, that were stockpiled before the patents expired.
Biogen And Millennium May Be Ensnared In Tentacles Of Genentech’s Expired Cabilly Patent
Genentech claims Biogen and Millennium owe royalties on sales of Tysabri and Entyvio that were stockpiled when the Cabilly patent expired. Hospira faced similar litigation over its erythropoietin biosimilar and had to pay Amgen $70m in damages.
